Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK - 9-13 November 2008

J Int AIDS Soc 2008, 11(Suppl 1):21 doi:10.1186/1758-2652-11-S1-O21

DM Gibb¹, A Compagnucci², H Green³, M Lallemant⁴, Y Saidi², N Ngo-Giang-Huong⁴, C Taylor³, L Mofenson⁵, F Monpoux⁶, MIG Tomé⁷, M Marczyñska⁸, D Nadal⁹, U Wintergerst¹⁰, S Kanjavanit¹¹, H Lyall¹², C Giaquinto¹³ and J Moye^4
1 MRC, London, UK ² INSERM SC10, Paris, France ³ Medical Research Council Clinical Trials Unit, London, UK ⁴ IRD, Chiang Mai University, Chiang Mai, Thailand ⁵ Enice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, MD, USA ⁶ Hôpital de l'Archet, Nice, France ⁷ Hospital Materno Infantil, Madrid, Spain ⁸ Medical University of Warsaw, Warsaw, Poland ⁹ University Children's Hospital of Zurich, Zurich, Switzerland ¹⁰ Universitäts-kinderkliniken, Munich, Germany ¹¹ Nakornping Hospital, Chiang Mai, Thailand ¹² St Mary's Hospital, London, UK ¹³ Universitá di Padova, Padova, Italy

BACKGROUND: Compared to adults, children are likely to spend longer on antiretroviral treatment (ART), particularly if ART is started in infancy, and may respond differently to PTIs due to higher thymic activity.

METHODS: PENTA 11 was a Phase II randomised trial to compare CD4-guided PTI with continuous therapy (CT) in children with confirmed viral load (VL) < 50 c/ml, and CD4% ≥ 30% (ages 2–6 years) or CD4% ≥ 25% and CD4 ≥ 500 cells/mm³ (7–15 years). In the PTI arm, ART was restarted if confirmed CD4% < 20% (< 7 years) or CD4% < 20% or CD4 < 350 cells/mm³ (≥ 7 years). Additional precautions were subsequently added; duration of a PTI should not exceed 48 weeks and further PTIs undertaken only in children who spent >10 weeks off ART during 1^st PTI and had been back on ART for 24 weeks. The primary endpoint was CD4% < 15% (and CD4 < 200 cells/mm³ ≥ 7 years), or CDC C event or death. Children were followed until the last randomised child completed 72 weeks follow-up. All comparisons were intention-to-treat.

SUMMARY OF RESULTS: From 2004 to 2006, 109 children from nine countries were randomised to CT (53) or PTI (56): 45% male, median age 9 (range 2–16) years; 35% white, 31% black; 26% CDC stage C, median time on ART 6 years. Median baseline CD4% was 37% (IQR: 33,41), CD4 966 (793,1258) cells/mm³; prior to ART nadir CD4% 18% (10,27) and CD4 627 (320,1050) cells/mm³. After median 130 (80,144) weeks follow-up (one child lost), 4% of time was spent off ART in CT vs. 48% in PTI. On 1^st PTI 21 (38%) children restarted ART before 48 weeks (14 protocol, seven other reasons); 32 (57%) restarted at 48 weeks and three remained off ART. 16 children had a 2^nd PTI. No child died or had a CDC C event; 1 CT vs. 4 PTI children had a CD4 end-point (p=0.4); 98.4% vs. 95.9% of time was spent with CD4 = 350 cells/mm³. Mean CD4 change from 0–72 weeks was –106 vs. –240 cells/mm³ in CT vs. PTI (difference –134 cells/mm³, 95% CI –237, –31, p=0.01; six children were off ART in PTI). However, mean CD4 change 0–72 weeks was –124 cells/mm³ in 27 children in the PTI arm who had been back on ART for ≥ 24 weeks. In the PTI arm CD4 recovery adjusted for age appeared better in younger children (CD4 z-score change from 0–24 weeks after restarting –0.1, –0.9, –1.3 for ages 2–6, 7–10 and 11+ years, respectively, p=0.02). At 72 weeks, 94%/ 85% vs. 81%/58% children had VL < 400/< 50 c/ml in CT vs PTI (p=0.04/0.002). Of the 28 PTI children back on ART for ≥ 24 weeks, 89%/68% had VL < 400/< 50 c/ml.

CONCLUSION: In summary, PENTA 11 was the first randomised trial of planned treatment interruptions (PTIs) in children with chronic HIV infection. In this pilot study we observed no deaths or serious clinical events. Overall, fewer PTI children were suppressed < 50 c/ml at 72 weeks (analysis of resistance results is ongoing) and CD4 recovery after PTI appeared better in younger children. However, longer-term assessment of all children after restarting ART will be required to fully assess risks and benefits of PTI in this population.

2008-11-10
1758-2652-11-S1-O21

Copyright © 2008 Gibb et al; licensee BioMed Central Ltd

This information is designed to support, not replace, the relationship that exists between you and your doctor.
1980, 2009. AEGiS.